August 16, 2021

Anticancer Agent “Tazverik Tablets 200mg” (Tazemetostat Hydrobromide) Launched in Japan for EZH2 Gene Mutation-Positive Follicular Lymphoma

TOKYO, Aug 16, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that it has launched the anticancer agent EZH2 inhibitor “Tazverik…

June 23, 2021

Anticancer Agent “Tazverik Tablets 200mg” (Tazemetostat Hydrobromide) Approved In Japan For EZH2 Gene Mutation-positive Follicular Lymphoma

TOKYO, Jun 23, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that it has obtained manufacturing and marketing approval for the…